Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Completed 3Unknown 1Terminated 1

Sponsor Class

OTHER 14INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 5Pain 4Cancer Pain 4Substance Withdrawal Syndrome 1Opioid-Related Disorders 1Lymphoma, Follicular 1Chronic Pain 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × Morphine × Clear all
NCT03564548 2021-07-28

REBORN

Tetra Bio-Pharma

Phase 2 Unknown
20 enrolled
Tumor-Agnostic

Neoplasms

NCT00505414 2019-11-01

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

Grünenthal GmbH

Phase 3 Terminated
136 enrolled 9 charts

Neoplasms, Pain

NCT01675622 2018-05-21

Immediate-Release Oxycodone Capsules Study in Cancer Pain

Mundipharma (China) Pharmaceutical Co. Ltd

Phase 3 Completed
242 enrolled 20 charts

Cancer Pain, Neoplasms

NCT00446069 2016-08-29

A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients

Egalet Ltd

Phase 2 Completed
36 enrolled

Neoplasms, Pain

NCT01309386 2013-03-13

A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants

Janssen Pharmaceutical K.K.

Phase 3 Completed
100 enrolled 12 charts

Cancer Pain, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡